Syncrosome as Event Partner of 3rd HF Drug Discovery & Development Summit in Boston
Syncrosome is proud to attend the next Heart Failure Drug Discovery & Development Summit as an event partner, which will take place from 31 July to 1 August 2024, in Boston (USA, MA)! We look forward to participating in the 3rd HF Drug Discovery & Development Summit, which returns to tackle the major challenges facing preclinical heart failure drug development by bringing together more than 50 biopharmas delve into targeting, stratifying and treating cardiomyopathies with greater precision. A fine programme of scientific
ETAP-Lab interview on IBTV
📺 ETAP-Lab talks to IBTV at BIO 2024 about our current projects and activity, and to present our innovations. Jérôme Bernard, CBO, explains: "As a CRO, we have to be at the forefront of innovation to help our clients to derisk their molecules and programs". ▶️ Discover the integral interview on IBTV channel.
Meet ETAP-Lab at the FENS Forum 2024 – Booth 1004
ETAP-Lab will attend the upcoming FENS Forum 2024 on next June 26-29, 2024, in Vienna (Austria). FENS Forum 2024, taking place in Vienna this year, is organized by the Federation of European Neuroscience Societies (FENS), the Austrian Neuroscience Association (ANA) and the Hungarian Neuroscience Society. The FENS Forum is Europe’s largest neuroscience congress, covering all areas of neuroscience from basic to translational research. It will feature an exciting programme of plenary and special lectures, scientific symposia, technical workshops, special interest events,
Rendez-vous aux JAS 2024 – Congrès Nutrition Santé à La Rochelle
ETAP-Lab sera présent aux Journées Aliments & Santé à La Rochelle (France) le 19 et 20 juin 2024 - créées à l’initiative du CRITT Agro-Alimentaire de La Rochelle - manifestation de référence pour les professionnels de l’agro-alimentaire et la plus importante convention d’affaires européenne du secteur. 🍏 Découvrez nos solutions dédiées à l'industrie agroalimentaire Nous souhaitons rencontrer des laboratoires pour les accompagner dans l'évaluation de leurs ingrédients naturels, fonctionnels et nouveaux aliments, et soutenir leur R&D pour répondre aux enjeux de l'alimentation
Nextmed Day – ETAP-Lab taking part in a round table
Discover on 13 June in Strasbourg the Nextmed Day: bringing the future of healthcare closer together! ➡ETAP-Lab, represented by its CEO Nicolas Violle, will be taking part in the round table "France 2030: how to support excellence in the healthcare sector in the territories?" This round table will be featuring Charles-Edouard Escurat from the Agence de l'Innovation en santé, Jean-Luc Dimarcq from the IHU Strasbourg, and moderated by Jean Sibilia. 👉 You can find the full programme with other round tables and pitches
First #fluorescencefriday – the word of our expert
🔬 We wanted to share with you one of our cell image that shows primary cortical rat neurons (DIV14) stained for PSD-95 (synapses) in green, MAP2 (dendrites) in red and DAPI (nuclei) in blue. Each little green dot shows an active synapse happening between two neurons! 🧠Ahmad Allouche, one of our in vitro expert, explains: "About the synaptic degeneration mechanism, it occurs early in neurodegenerative diseases and correlates with cognitive decline. Increased levels of synaptic proteins have been detected in the CSF
ETAP-Lab to attend the 2024 BIO International Convention for Partnering Opportunities
ETAP-Lab, including its brands SYNCROSOME and STROK@LLIANCE, will attend the upcoming 2024 BIO International Convention on next June 3 - 6, 2024, in San Diego, California for partnering opportunities. This annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering, bringing together thousands of global biotechnology and biopharmaceutical leaders. 🎯 Our broad offering, tailored to your challenges You look forward accelerating the development of your drugs and/or medical devices in Dermatology, Neurology, Gastroenterology or Cardiology thanks to preclinical studies
World Parkinson’s Day 2024 – Towards improved screening tools for Parkinson’s disease
🌍Today is World Parkinson’s Day, dedicated to increase public awareness and understanding of this disease which affects over 10 million people worldwide, making it the second leading of neurodegenerative disease after Alzheimer's. It is also the second most common cause of motor disability after stroke. It is considered that almost 1 in 50 people will be directly affected by this disease during their lifetime. Although widespread, there is currently no cure for the disease. In the Parkinson's disease field, the notion
Poster AD/PD International Conference | Brain-On-Chip Project
🧠 March 5-9 - Lisbon - AD/PD International Conference | Explore the research findings of ETAP-Lab and NETRI from the BIO-DIAMOND project at the poster titled :Advancing Alzheimer's Disease Models for Target Validation and Drug Discovery. 🔬 Meet our expert, Dr. Ahmad ALLOUCHE, and learn more about this project. 💡 We are proud to present our innovative #BrainOnChip model designed to develop and explore drug efficacy in #Alzheimer's disease. Our model incorporates: > Compartmentalized co-culture, showcased in the poster, featuring glutamatergic and GABAergic neurons derived from human induced pluripotent
Improving Stroke Outcomes in Hyperglycemic Mice by Modulating tPA/NMDAR Signaling to Reduce Inflammation and Hemorrhages
The pharmacological intervention for ischemic stroke hinges on intravenous administration of the recombinant tissue-type plasminogen activator (rtPA, Alteplase/Actilyse®) either as a standalone treatment or in conjunction with thrombectomy. However, despite its clinical significance, broader employment of rtPA is constrained due to the risk of hemorrhagic transformations (HTs). Furthermore, the presence of diabetes or chronic hyperglycemia is associated with an elevated risk of HT subsequent to thrombolysis. This detrimental impact of tPA on the neurovascular unit in hyperglycemic patients has been